Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

C4 Therapeutics (CCCC) EBIT (2019 - 2026)

C4 Therapeutics has reported EBIT over the past 8 years, most recently at -$27.8 million for Q1 2026.

  • For Q1 2026, EBIT rose 4.73% year-over-year to -$27.8 million; the TTM value through Mar 2026 reached -$113.8 million, up 2.33%, while the annual FY2025 figure was -$115.2 million, 3.67% up from the prior year.
  • EBIT for Q1 2026 was -$27.8 million at C4 Therapeutics, down from -$23.1 million in the prior quarter.
  • Over five years, EBIT peaked at -$21.4 million in Q2 2024 and troughed at -$38.3 million in Q4 2022.
  • A 5-year average of -$31.2 million and a median of -$31.4 million in 2022 define the central range for EBIT.
  • Biggest five-year swings in EBIT: crashed 151.02% in 2022 and later surged 42.92% in 2024.
  • Year by year, EBIT stood at -$38.3 million in 2022, then grew by 2.26% to -$37.4 million in 2023, then dropped by 0.75% to -$37.7 million in 2024, then surged by 38.62% to -$23.1 million in 2025, then decreased by 20.05% to -$27.8 million in 2026.
  • Business Quant data shows EBIT for CCCC at -$27.8 million in Q1 2026, -$23.1 million in Q4 2025, and -$34.4 million in Q3 2025.